SCHEMBL16129652

SCHEMBL16129652

COCCCOCc1ccc(C(=O)Nc2ccc(-c3ccccc3)cc2)cc1[N+](=O)[O-]

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
TDP1 Q9NUW8 2/20 0.53
CYP3A4 P08684 1/20 0.53
TSHR P16473 1/20 0.53
MEN1 O00255 7/20 0.53
KMT2A Q03164 7/20 0.53
MAPT P10636 6/20 0.52
NPC1 O15118 2/20 0.48
MAPK1 P28482 1/20 0.48
HTT P42858 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
ABCB1 P08183 3/20 0.48
LMNA P02545 2/20 0.48
GAA P10253 1/20 0.47
PLG P00747 1/20 0.46
PLAU P00749 1/20 0.46
PLAT P00750 1/20 0.46
RECQL P46063 2/20 0.45
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16098795 0.94 ALDH1A1 (0.55) ALDH1A1TDP1CYP3A4TSHRMEN1
SCHEMBL16098445 0.90 ALDH1A1 (0.60) ALDH1A1TDP1CYP3A4TSHRMEN1
SCHEMBL16129712 0.84 PTPN1 (0.47) MEN1KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL16129649 0.82 HCAR3 (0.56) ALDH1A1TSHRMEN1KMT2AMAPT
SCHEMBL16098779 0.80 SMN1; SMN2 (0.47) ALDH1A1MEN1KMT2AMAPTNPC1
SCHEMBL16099072 0.79 ALDH1A1 (0.53) ALDH1A1TDP1CYP3A4TSHRMEN1
SCHEMBL16098533 0.78 ALDH1A1 (0.86) ALDH1A1TDP1CYP3A4TSHRMEN1
SCHEMBL16096914 0.77 PTPN1 (0.49) MEN1KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL6814247 0.76 MEN1 (0.70) ALDH1A1TDP1CYP3A4TSHRMEN1
SCHEMBL17511817 0.75 HCAR3 (0.58) TSHRMEN1KMT2AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160052898-A1 NOVEL COMPOUNDS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-02-25 US disclosed
US-20160052898-A1 NOVEL COMPOUNDS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-02-25 US disclosed
WO-2014147182-A2 NOVEL COMPOUNDS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052898-A1 NOVEL COMPOUNDS AADAC, NAT1, CCNA1 ALDH1A1 325/4885TDP1 1992/4885CYP3A4 1384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.